Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Meningococcal Vaccine”

393 trials

Showing 20 of 393 results

Post-approval studies (Phase 4)Study completedNCT00271479
What this trial is testing

Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine

Who this might be right for
Infections, MeningococcalMeningitis, Meningococcic
Epicentre 720
Testing effectiveness (Phase 2)Study completedNCT04886154
What this trial is testing

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 1,440
Post-approval studies (Phase 4)Study completedNCT04450498
What this trial is testing

Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Who this might be right for
Neisseria Meningitides Meningitis
Walvax Biotechnology Co., Ltd. 260
Large-scale testing (Phase 3)Study completedNCT00944034
What this trial is testing

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 1,588
Large-scale testing (Phase 3)Study completedNCT04368429
What this trial is testing

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Who this might be right for
Meningococcal Immunisation (Healthy Volunteers)
Sanofi 360
Testing effectiveness (Phase 2)Study completedNCT00488683
What this trial is testing

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Who this might be right for
Meningococcal Disease
Novartis Vaccines 216
Testing effectiveness (Phase 2)Study completedNCT00262002
What this trial is testing

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants

Who this might be right for
Prevention of Meningococcal Disease
Novartis Vaccines 601
Post-approval studies (Phase 4)Study completedNCT01270503
What this trial is testing

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

Who this might be right for
MeningitisMeningococcal Disease
Sanofi Pasteur, a Sanofi Company 538
Large-scale testing (Phase 3)Study completedNCT03714737
What this trial is testing

Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese

Who this might be right for
Vaccine
Jiangsu Province Centers for Disease Control and Prevention 1,950
Not applicableStudy completedNCT01689155
What this trial is testing

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Who this might be right for
MeningitisMeningococcal Infection
Sanofi Pasteur, a Sanofi Company 116
Testing effectiveness (Phase 2)Study completedNCT03295318
What this trial is testing

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Who this might be right for
Meningitis, Meningococcal
Serum Institute of India Pvt. Ltd. 375
Large-scale testing (Phase 3)Study completedNCT03135834
What this trial is testing

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Who this might be right for
Meningococcal Vaccine
Pfizer 1,610
Post-approval studies (Phase 4)Study completedNCT00290329
What this trial is testing

Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 249
Large-scale testing (Phase 3)Study completedNCT00955682
What this trial is testing

Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 342
Testing effectiveness (Phase 2)Study completedNCT01367158
What this trial is testing

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 440
Large-scale testing (Phase 3)Study completedNCT01642589
What this trial is testing

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

Who this might be right for
MeningitisMeningococcal Disease
Sanofi Pasteur, a Sanofi Company 300
Early research (Phase 1)Study completedNCT00678652
What this trial is testing

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

Who this might be right for
Meningococcal Infection, Group B
U.S. Army Medical Research and Development Command 36
Early research (Phase 1)Study completedNCT01482052
What this trial is testing

Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis

Who this might be right for
Meningococcal MeningitisMeningococcal Infections
JN-International Medical Corporation 60
Testing effectiveness (Phase 2)Study completedNCT02946385
What this trial is testing

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Who this might be right for
Infections, Meningococcal
GlaxoSmithKline 604
Large-scale testing (Phase 3)Study completedNCT01148524
What this trial is testing

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Who this might be right for
Meningococcal DiseaseMeningococcal Meningitis
Novartis Vaccines 817
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation